Skip to main content
BHVN logo

BHVN · Biohaven Ltd. · Investor Relations

Track BHVN — free
$12.39 -1.26 (-9.23%) At close · Nov 20 Q4 2021 earnings call transcript
Market Cap
$1.87B
Shares
151.06M
Volume · Nov 20 2.39M Avg daily vol (3M) 3.22M

Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.

Recent news

Date Headline
2026-11-19 Biohaven's Novel FGFR3-Directed ADC with Proprietary TopoIx Payload, BHV-1530, Shows Clinical Activity and Confirmed Responses in FGFR3-Altered Urothelial and Head and Neck Cancers, Oral Presentation at ENA 2026
2026-11-05 Biohaven Drives New Research in Graves' Disease: Phase 3 Pivotal Trial with BHV-1300 Underway and Three Scientific Posters at the 2026 American Thyroid Association Annual (ATA) Meeting
2026-10-29 Biohaven Reports Recent Business Developments and Third Quarter 2026 Financial Results
2026-10-26 Biohaven Oral Presentation at ASN Kidney Week 2026 Spotlights BHV-1420, a Novel TRAP Degrader Designed to Selectively Remove the Autoantibodies that Drive Membranous Nephropathy
2026-10-15 Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease
2026-10-08 Biohaven Enters Strategic Licensing Agreement with Ono Pharma for Extracellular IgG Degraders in Japan and Select Asian Regions, Lead Candidate BHV-1300 in Phase 3 for Graves' Disease
2026-09-28 Biohaven's Clinical Data on BHV-1530, a Novel FGFR3-Directed ADC With a Proprietary Topoisomerase I (TopoIx) Payload, Selected for Oral Presentation at the EORTC-NCI-AACR Symposium 2026
2026-08-26 Biohaven and SK Biopharmaceuticals Enter into Strategic Global Licensing Agreement for Novel Kv7 Ion Channel Platform and Opakalim, Lead Candidate for Epilepsy
2026-08-10 Biohaven Reports Recent Business Developments and Second Quarter 2026 Financial Results
2026-05-27 Biohaven Reports Positive Clinical Biomarker and Patient Data: First MoDE and TRAP Extracellular Protein Degraders Achieve Deep, Rapid, Selective Lowering of Disease-Driving Antibodies in Graves' Disease and IgA Nephropathy
2026-05-27 Biohaven Reports New Clinical Data in Epilepsy with Opakalim, a Selective Kv7.2/7.3 Activator, Highlighting Seizure Control and Markedly Differentiated Tolerability Profile
2026-05-04 Biohaven Reports Recent Business Developments and First Quarter 2026 Financial Results
2026-03-02 Biohaven Reports Recent Business Developments and Fourth Quarter and Full Year 2025 Financial Results
2025-11-10 Biohaven Reports Third Quarter 2025 Financial Results and Recent Business Developments

Past events

Source: https://www.biohaven.com/investors

Key facts CIK 1935979 CUSIP G1110E107 13F (30d) 298 filings 272 filers Visit website Investor relations